Merck & Co. (MRK) Shares Sold by Dowling & Yahnke LLC

Dowling & Yahnke LLC lowered its position in Merck & Co. (NYSE:MRK) by 1.2% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 100,823 shares of the company’s stock after selling 1,231 shares during the period. Dowling & Yahnke LLC’s holdings in Merck & Co. were worth $5,492,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of MRK. Pacer Advisors Inc. lifted its position in Merck & Co. by 9.9% during the third quarter. Pacer Advisors Inc. now owns 99,776 shares of the company’s stock valued at $6,389,000 after purchasing an additional 9,020 shares in the last quarter. Willingdon Wealth Management lifted its position in Merck & Co. by 4.2% during the third quarter. Willingdon Wealth Management now owns 34,860 shares of the company’s stock valued at $2,232,000 after purchasing an additional 1,390 shares in the last quarter. Walter & Keenan Financial Consulting Co. MI ADV lifted its position in Merck & Co. by 3.4% during the third quarter. Walter & Keenan Financial Consulting Co. MI ADV now owns 37,207 shares of the company’s stock valued at $2,382,000 after purchasing an additional 1,225 shares in the last quarter. Sound Shore Management Inc. CT lifted its position in Merck & Co. by 6.7% during the third quarter. Sound Shore Management Inc. CT now owns 3,351,152 shares of the company’s stock valued at $214,574,000 after purchasing an additional 211,247 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Merck & Co. by 3.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,144,983 shares of the company’s stock valued at $73,314,000 after purchasing an additional 41,294 shares in the last quarter. 73.14% of the stock is owned by institutional investors.

In other news, EVP Julie L. Gerberding sold 9,972 shares of Merck & Co. stock in a transaction dated Tuesday, May 15th. The stock was sold at an average price of $59.66, for a total value of $594,929.52. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Weir Mirian M. Graddick sold 24,000 shares of Merck & Co. stock in a transaction dated Monday, April 16th. The stock was sold at an average price of $58.00, for a total value of $1,392,000.00. The disclosure for this sale can be found here. 0.32% of the stock is owned by insiders.

Shares of Merck & Co. stock opened at $58.45 on Wednesday. Merck & Co. has a 52 week low of $52.83 and a 52 week high of $66.41. The stock has a market capitalization of $157.92 billion, a PE ratio of 14.69, a price-to-earnings-growth ratio of 2.23 and a beta of 0.76. The company has a current ratio of 1.42, a quick ratio of 1.10 and a debt-to-equity ratio of 0.63.

Merck & Co. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, May 1st. The company reported $1.05 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.00 by $0.05. Merck & Co. had a return on equity of 30.93% and a net margin of 4.31%. The business had revenue of $10.04 billion for the quarter, compared to the consensus estimate of $10.09 billion. During the same period in the previous year, the business earned $0.88 earnings per share. The business’s revenue was up 6.4% on a year-over-year basis. equities research analysts anticipate that Merck & Co. will post 4.23 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, July 9th. Stockholders of record on Friday, June 15th will be given a $0.48 dividend. This represents a $1.92 annualized dividend and a dividend yield of 3.28%. Merck & Co.’s payout ratio is 48.24%.

Several research firms recently weighed in on MRK. Zacks Investment Research downgraded Merck & Co. from a “buy” rating to a “hold” rating in a research report on Wednesday, May 16th. Deutsche Bank reiterated a “hold” rating on shares of Merck & Co. in a research report on Wednesday, April 25th. BMO Capital Markets reiterated a “buy” rating on shares of Merck & Co. in a research report on Wednesday, April 25th. Leerink Swann lowered their target price on Merck & Co. from $69.00 to $67.00 and set a “market perform” rating on the stock in a research report on Tuesday, February 6th. Finally, Jefferies Group set a $55.00 target price on Merck & Co. and gave the company a “hold” rating in a research report on Friday, March 23rd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $65.87.

Merck & Co. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Institutional Ownership by Quarter for Merck & Co. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply